Sun Pharma Advanced Research Company Q3 FY26 Share Price & Earnings Call Analysis
- Market cap
- ₹5,941 Cr
- P/E
- 3.72
- ROE
- 281.12%
- PEG
- 0.04
- Price to sales
- 3.11
- Debt to equity
- 0.42
- 52W high / low
- ₹278 / ₹109
- Sales growth (5Y)
- 49.34%
- EBITDA margin
- 84.62%
- Net profit margin
- 83.25%
- Promoter holding
- 65.68%
- Sales (last year)
- ₹1,909 Cr
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]
Guidance scorecard · Q3 FY26 call
What Sun Pharma Advanced Research Company Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ3 FY26 call
- SPARC is prioritizing execution on two key clinical programs: MUC1 ADC in solid tumors and SCD-153 for alopecia areata, with early clinical proof-of-concept expected between late 2026 and 2027.
- Focused portfolio reshaping around oncology and immunology themes aims to unlock medium- to long-term value.
- Cost optimization efforts, including reduction of fixed costs by approximately $10 million annually, support scalable growth.
- Expansion of clinical programs, including addition of vitiligo trial and radio/chemosensitizer, will drive pipeline diversification.
- Collaboration with partners like Tiller Therapeutics to advance small molecule drug conjugates (SMDCs) supports potential new product launches.
- Progress on key regulatory milestones, such as Maximum Tolerated Dose (MTD) identification and IND filings, will facilitate advancement to pivotal trials.
2 more points from Sun Pharma Advanced Research Company Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ3 FY26 call
FlatSee what Sun Pharma Advanced Research Company Ltd said on margins — free account, 30 seconds.
CapexQ3 FY26 call
Planned- SPARC has been focusing on aggressive portfolio building and scaling clinical programs.
- They strategically increased the India component of clinical development to reduce costs and enhance efficiency.
- Cost structure optimization has been significant, including reducing headcount (from 400+ to ~250) and lab centers (from 4 to 2).
- Outsourcing certain costly infrastructure capabilities to manage fixed costs.
- They are finalizing a funding plan to extend the cash runway to FY '28, aiming to complete this process in the first half of calendar year 2026.
2 more points from Sun Pharma Advanced Research Company Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ3 FY26 call
PlannedSee what Sun Pharma Advanced Research Company Ltd said on fundraising — free account, 30 seconds.
Order bookQ3 FY26 call
Ask what Sun Pharma Advanced Research Company Ltd said on the order book →
Full Q3 FY26 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Sun Pharma Advanced Research Company Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Sun Pharma Advanced Research Company Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Sun Pharma Advanced Research Company Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 48 | 24 | 21 | 14 | 17 | 17 | 13 | 15 | 27 | 10 | 8 | 8 | 1,853 |
| Expenses + | 137 | 126 | 113 | 116 | 124 | 112 | 117 | 89 | 81 | 62 | 74 | 65 | 80 |
| Operating Profit | -90 | -102 | -91 | -103 | -108 | -95 | -104 | -74 | -54 | -52 | -66 | -57 | 1,773 |
| OPM % | -188% | -427% | -432% | -740% | -649% | -566% | -808% | -499% | -198% | -543% | -838% | -673% | 96% |
| Other Income + | 11 | 10 | 8 | 6 | 4 | 2 | 0 | 0 | 0 | 9 | 0 | -12 | 2 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 | 8 | 9 | 12 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 |
| Profit before tax | -82 | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 | -52 | -76 | -81 | 1,761 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit + | -82 | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 | -52 | -76 | -81 | 1,761 |
| EPS in Rs | -2.53 | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 | -3.32 | -2.46 | -1.88 | -1.60 | -2.34 | -2.48 | 54.26 |
Financials of Sun Pharma Advanced Research Company Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 156 | 161 | 181 | 78 | 183 | 77 | 253 | 137 | 239 | 76 | 72 | 1,879 |
| Expenses + | 191 | 224 | 304 | 321 | 334 | 387 | 388 | 324 | 453 | 479 | 399 | 281 |
| Operating Profit | -35 | -63 | -123 | -243 | -151 | -310 | -135 | -187 | -214 | -404 | -327 | 1,598 |
| OPM % | -23% | -39% | -68% | -310% | -83% | -404% | -53% | -136% | -90% | -534% | -456% | 85% |
| Other Income + | 3 | 3 | 14 | 54 | 14 | 10 | 5 | 7 | 11 | 29 | 2 | -2 |
| Interest | 0 | 2 | 2 | 0 | 0 | 3 | 11 | 13 | 8 | 2 | 9 | 34 |
| Depreciation | 7 | 8 | 8 | 8 | 8 | 9 | 11 | 10 | 12 | 12 | 11 | 10 |
| Profit before tax | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -223 | -388 | -345 | 1,552 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit + | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -223 | -388 | -345 | 1,552 |
| EPS in Rs | -1.60 | -2.83 | -4.82 | -7.85 | -5.55 | -11.92 | -5.77 | -7.48 | -6.86 | -11.96 | -10.64 | 47.83 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Sun Pharma Advanced Research Company Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 25 | 25 | 26 | 26 | 26 | 27 | 32 | 32 | 32 | 32 |
| Reserves | 76 | 8 | 133 | 160 | 270 | -45 | -194 | 4 | 480 | 92 | -253 | 1,301 |
| Borrowings + | 4 | 56 | 3 | 2 | 2 | 67 | 236 | 79 | 16 | 56 | 265 | 559 |
| Other Liabilities + | 39 | 75 | 111 | 122 | 101 | 224 | 162 | 170 | 302 | 305 | 284 | 275 |
| Total Liabilities | 143 | 163 | 273 | 309 | 398 | 273 | 230 | 280 | 830 | 486 | 329 | 2,168 |
| Fixed Assets + | 67 | 70 | 69 | 52 | 58 | 104 | 91 | 92 | 106 | 103 | 95 | 157 |
| CWIP | 0 | 1 | 1 | 3 | 24 | 32 | 5 | 26 | 27 | 44 | 54 | 0 |
| Investments | 0 | 0 | 10 | 108 | 211 | 8 | 6 | 12 | 291 | 2 | 0 | 0 |
| Other Assets + | 76 | 92 | 192 | 146 | 106 | 128 | 127 | 150 | 406 | 338 | 179 | 2,011 |
| Total Assets | 143 | 163 | 273 | 309 | 398 | 273 | 230 | 280 | 830 | 486 | 329 | 2,168 |
Financials of Sun Pharma Advanced Research Company Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -41 | -44 | -128 | -183 | -172 | -211 | -152 | -208 | -69 | -429 | -362 | -239 |
| Cash from Investing Activity + | 53 | -13 | -7 | -105 | -102 | 155 | 2 | -29 | -548 | 391 | 158 | -24 |
| Cash from Financing Activity + | -1 | 51 | 194 | 224 | 274 | 55 | 159 | 229 | 617 | 43 | 201 | 262 |
| Net Cash Flow | 11 | -7 | 60 | -63 | 0 | 0 | 9 | -8 | -1 | 4 | -4 | -1 |
| Free Cash Flow | -49 | -56 | -136 | -200 | -184 | -264 | -153 | -233 | -84 | -455 | -372 | -262 |
| CFO/OP | 110% | 48% | 88% | 71% | 111% | 65% | 111% | 114% | 35% | 105% | 114% | -17% |
Financials of Sun Pharma Advanced Research Company Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 21 | 78 | 82 | 20 | 76 | 25 | 74 | 50 | 75 | 82 | 2 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 47 | 21 | 78 | 82 | 20 | 76 | 25 | 74 | 50 | 75 | 82 | 2 |
| Working Capital Days | 20 | -161 | -60 | -232 | -98 | -842 | -268 | -301 | -193 | -746 | -1,778 | 214 |
| ROCE % | -32% | -71% | -94% | -143% | -62% | -183% | -242% | -218% | -67% | -109% | -298% | 165% |
Momentum score · price trend
35 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +32.9% | 79% |
| Last 6 months | +27.9% | 79% |
| Last 3 months | −12.2% | 34% |
The price is 64.5% below its all-time high of ₹516 (12 Jan 2018). Stocks more than 20% below their peak have their score halved, so 70 became 35.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Sun Pharma Advanced Research Company Ltd: 0.4 × 79 + 0.4 × 79 + 0.2 × 34 = 70, halved to 35 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Sun Pharma Advanced Research Company Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY